Sangamo Biosciences (SGMO) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Janney Montgomery Scott Downgrades Sangamo BioSciences (SGMO) to Neutral
August 4, 2016 7:25 AM EDTJanney Montgomery Scott downgraded Sangamo BioSciences (NASDAQ: SGMO) from Buy to Neutral with a price target of $8.00 (from $15.00).
For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.
Shares of Sangamo BioSciences closed at $6.84 yesterday.
... More